Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Gains from Investment Securities (2021 - 2025)

Prime Medicine (PRME) has disclosed Gains from Investment Securities for 5 consecutive years, with $539000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 98.81% year-over-year to $539000.0, compared with a TTM value of $432000.0 through Dec 2025, down 99.04%, and an annual FY2025 reading of $432000.0, down 99.04% over the prior year.
  • Gains from Investment Securities was $539000.0 for Q4 2025 at Prime Medicine, down from $1.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $45.5 million in Q4 2024 and bottomed at -$8.2 million in Q2 2022.
  • Average Gains from Investment Securities over 5 years is $6.0 million, with a median of $587000.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities skyrocketed 7062.05% in 2024, then crashed 190.57% in 2025.
  • Year by year, Gains from Investment Securities stood at $12.3 million in 2021, then skyrocketed by 200.05% to $36.8 million in 2022, then tumbled by 98.27% to $635000.0 in 2023, then surged by 7062.05% to $45.5 million in 2024, then plummeted by 98.81% to $539000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for PRME at $539000.0 in Q4 2025, $1.5 million in Q3 2025, and -$505000.0 in Q2 2025.